Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00345813 · ClinicalTrials.gov registry record · Phase 2
Soy Supplements in Treating Patients Undergoing Surgery for Localized Prostate Cancer
A Phase 2 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
NCT00345813 is a Phase 2 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 62 participants.
The verdict
NCT00345813, a Phase 2 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
Study Summary
RATIONALE: Dietary supplementation with soy may keep prostate cancer from growing in patients planning to undergo surgery. PURPOSE: This randomized phase II trial is studying a soy supplement to see how well it works compared to a placebo in treating patients undergoing surgery for localized prostate cancer.
Interventions
- OTHER placebo
- DIETARY_SUPPLEMENT soy protein isolate
- DIETARY_SUPPLEMENT soy isoflavones
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2003-10 |
| Est. Completion | 2006-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00345813
The ClinicalTrials.gov registry entry for NCT00345813 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00345813 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00345813 about?
NCT00345813 is a clinical study titled "Soy Supplements in Treating Patients Undergoing Surgery for Localized Prostate Cancer". RATIONALE: Dietary supplementation with soy may keep prostate cancer from growing in patients planning to undergo surgery. PURPOSE: This randomized phase II trial is studying a soy supplement to see how well it works compared to a placebo in treating patients undergoing surgery for localized prosta...
What is the current status of trial NCT00345813?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2003-10. Estimated completion is 2006-07.
What interventions are being tested in trial NCT00345813?
The interventions under investigation include: placebo (OTHER), soy protein isolate (DIETARY_SUPPLEMENT), soy isoflavones (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00345813?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.